I joined the LMS Psychiatric Imaging Research Group in 2021 with a Marie Skłodowska-Curie Individual Fellowship aimed at testing new candidate antipsychotic drugs targeting the trace amine-associated receptor 1 (TAAR1). This gave me the opportunity to conduct a research plan with immediate translational power for schizophrenia treatment. I apply molecular neuroimaging in animal models to interrogate neurobiological circuits underlying schizophrenia and pursue discovery of novel antipsychotic drugs. I translate my research to clinical trials in patients with schizophrenia, using PET and MRI imaging to assess drug effects on neurotransmission.